A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer

Gastrointestinal Cancer Research

Volumn 5, Issue 4, 2012, Pages 112-118

  Bapsi Chakravarthy, A ^a   Tsai, Chiao Jillian ^a   O'Brien, Nathan ^a   Craig Lockhart, A ^a   Chan, Emily ^a   Parikh, Alexander ^a   Berlin, Jordan D ^a   Merchant, Nipun ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; BICARBONATE; CETUXIMAB; GEMCITABINE; HEMOGLOBIN; MAGNESIUM; POTASSIUM; SODIUM;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BICARBONATE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; DEHYDRATION; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; DYSPNEA; ESOPHAGITIS; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HERPES SIMPLEX; HOT FLUSH; HUMAN; HYPOTENSION; HYPOXIA; ILEUS; INFECTION; INJECTION SITE REACTION; INOPERABLE CANCER; LIVER FUNCTION TEST; LOADING DRUG DOSE; MAGNESIUM BLOOD LEVEL; MAINTENANCE DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROPATHY; ODYNOPHAGIA; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHYSICAL PERFORMANCE; PNEUMONIA; POTASSIUM BLOOD LEVEL; RADIATION DOSE FRACTIONATION; RADIATION INDUCED EMESIS; RADIATION SICKNESS; SIDE EFFECT; SKIN FISSURE; SODIUM BLOOD LEVEL; THROMBOCYTE; THROMBOCYTE COUNT; TREATMENT DURATION;

EID: 84867872707     PISSN: 19347820     EISSN: 19347987     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. American Cancer Society: Cancer Facts and Figures. Atlanta, GA: ASC, 2012. Available at: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2012
2. Wolff RA, Evans DB, Gravel DM, et al: Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7:2246-2253, 2001
3. Ikeda M, Okada S, Tokuuye K, et al: A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 86:1551-1554, 2002
4. McGinn CJ, Zalupski MM, Shureiqi I, et al: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19:4202-4208, 2001
5. Korc M, Chandrasekar B, Yamanaka Y, et al: Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Oncol 90:1352-1360, 1992
6. Overholser JP, Prewett MC, Hooper AT, et al: Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89:74-82, 2000
7. Bruns CJ, Harbison MT, Davis DW, et al: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936-1948, 2000
8. Xiong HQ, Rosenberg A, LoBuglio A, et al: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22:2610-2616, 2004
9. Robert F, Ezekiel MP, Spencer SA, et al: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234-3243, 2001
10. Poggi MM, Kroog GS, Russo A, et al: Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 54:670-676, 2002
11. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). June 9, 2006. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
12. Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28:3605-3610, 2010
13. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
14. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
15. Arnoletti JP, Frolov A, Eloubeidi M, et al: A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemother Pharmacol 67:891-897, 2011
16. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
17. O'Neil BH, Allen R, Spigel DR, et al: High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 25:3644-3648, 2007
18. Chung CH, Mirakhur B, Chan E, et al: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358:1109-1117, 2008
19. Demols A, Mahin C, Maréchal R, et al: Cetuximab plus chemoradiation combined therapy for locally advanced inoperable pancreatic adenocarcinoma: a phase I study. J Clin Oncol 26:May 20 suppl, 2008 (abstr 4629)
20. Munter M, Tinke A, Abdollahi H, et al: Final results of a phase II trial [PARC-Study ISCRTN56652283] for patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated radiotherapy (IMRT) with cetuximab and gemcitabine. J Clin Oncol 26:May 20 suppl, 2008 (abstr 4613)
21. Crane CH, Varadhachary GR, Yordy JS, et al: Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29:3037-3043, 2011
22. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004
23. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004
24. Lievre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995, 2006
25. Yen LC, Uen YH, Wu DC, et al: Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 251:254-260, 2010
26. Almoguera C, Shibata D, Forrester K, et al: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554, 1988